In 2018, the pan-Janus kinase (JAK) inhibitor tofacitinib was launched for the treatment of
ulcerative colitis (UC). Although tofacitinib has proven efficacious in patients with active UC …

Cytokines are involved in intestinal homeostasis and pathological processes associated
with inflammatory bowel disease (IBD). The biological effects of cytokines, including several …

Crohn's disease (CD) and ulcerative colitis (UC), the main forms of inflammatory bowel
disease (IBD) in human beings, are chronic relapsing-remitting disorders of the …

Under current therapeutic algorithms, half of the patients with moderate-severe ulcerative
colitis or Crohn's disease fail in achieving a sustained remission. New drugs with different …

The two major forms of inflammatory bowel disease (IBD), encompassing Crohn's disease
(CD) and ulcerative colitis (UC), are chronic immune-mediated conditions characterised by …

Primary non-response and secondary loss of response remain a significant issue with the
currently available treatment options for a significant proportion of patients with inflammatory …

Introduction: Current available treatments for inflammatory bowel disease (IBD) have some
limitations and new options are needed. Several new molecules are being tested for the …

The inflammatory diseases ulcerative colitis and Crohn's disease constitute the two main
forms of inflammatory bowel disease (IBD). They are characterized by chronic, relapsing …

Abstract Background Janus kinases (JAKs) mediate cytokine signaling involved in
inflammatory bowel disease. The pan-JAK inhibitor tofacitinib has shown efficacy in the …

Although development of biologics has importantly improved the effectiveness in inducing
and maintaining remission in inflammatory bowel disease (IBD), biologic therapies still have …